

Going Public: An Inside Look at IPO Preparation for Life Science Companies

DECEMBER 5, 2012

With a boost provided by the JOBS Act and a number of recent successful IPOs in the industry, the IPO window remains open for life sciences companies. Before embarking on the IPO journey, however, companies need to understand the legal and market issues involved, many of which are unique to the industry.

Panelists from WilmerHale, Leerink Swann and Ernst & Young will be joined by the CEO of Merrimack Pharmaceuticals (which successfully completed an IPO this spring) to discuss:

- current and anticipated life sciences IPO market conditions;
- common characteristics of successful life sciences IPOs;
- tips for avoiding pitfalls often encountered in life sciences IPOs;
- the impact of the JOBS Act;
- alternative "going public" structures; and
- the experiences of life sciences companies that have recently gone public.

Please join us for this timely and informative event, highlighting IPO trends and issues specific to the life sciences industry. Each pre-IPO company in attendance will receive a complimentary copy of the new edition of WilmerHale's acclaimed book *Initial Public Offerings: A Practical Guide to Going Public*, hitting shelves in late 2012.

[READ MORE ABOUT THE EVENT](#)

Speakers

David E. Redlick

RETIRED PARTNER

📍 BOSTON

📞 + 1 617 526 6000



Brian A. Johnson

PARTNER

✉ brian.johnson@wilmerhale.com

📍 NEW YORK

📞 + 1 212 937 7206

You May Be Interested In



FIA Law & Compliance Division Conference 2024

APRIL 24–26, 2024

SPEAKING ENGAGEMENT





18th Annual Flagship Conference on Economic Sanctions Enforcement and Compliance

APRIL 29, 2024

SPEAKING ENGAGEMENT



Essentials of the European Union's Artificial Intelligence Act

MAY 2, 2024

WEBINAR

[VIEW ALL EVENTS](#)